

UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION

**IN RE: INVOKANA (CANAGLIFLOZIN)
PRODUCTS LIABILITY LITIGATION**

MDL No. 2750

(SEE ATTACHED SCHEDULE)


CONDITIONAL TRANSFER ORDER (CTO -1)

On December 7, 2016, the Panel transferred 18 civil action(s) to the United States District Court for the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See* F.Supp.3d (J.P.M.L. 2016). Since that time, no additional action(s) have been transferred to the District of New Jersey. With the consent of that court, all such actions have been assigned to the Honorable Brian R. Martinotti.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the District of New Jersey and assigned to Judge Martinotti.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the District of New Jersey for the reasons stated in the order of December 7, 2016, and, with the consent of that court, assigned to the Honorable Brian R. Martinotti.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.



FOR THE PANEL:



Jeffery N. Lüthi
Clerk of the Panel

I HEREBY CERTIFY that the above and foregoing is a true and correct copy of the original on file in my office.

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
WILLIAM T. WALSH, CLERK

By 
Deputy Clerk

**IN RE: INVOKANA (CANAGLIFLOZIN)
PRODUCTS LIABILITY LITIGATION**

MDL No. 2750

SCHEDULE CTO-1 – TAG-ALONG ACTIONS

<u>DIST</u>	<u>DIV.</u>	<u>C.A.NO.</u>	<u>CASE CAPTION</u>
CALIFORNIA CENTRAL			
CAC	5	16-02020	Lois Mercado v. Janssen Research and Development, LLC et al
FLORIDA NORTHERN			
FLN	5	16-00281	KAMPE v. JANSSEN PHARMACEUTICALS INC
ILLINOIS CENTRAL			
ILC	1	16-01406	Cape v. Janssen Ortho LLC et al
ILLINOIS NORTHERN			
ILN	1	16-09441	Faedtke v. Janssen Pharmaceuticals, Inc.
ILLINOIS SOUTHERN			
ILS	3	16-01140	Klein v. Janssen Pharmaceuticals, Inc.
KENTUCKY EASTERN			
KYE	0	16-00065	Moore et al v. Janssen Research & Development, LLC et al
KENTUCKY WESTERN			
KYW	3	16-00658	Tindle v. Janssen Pharmaceuticals, Inc. et al
LOUISIANA EASTERN			
LAE	2	16-16678	Vetter v. Janssen Pharmaceuticals, Inc. et al
MISSOURI EASTERN			
MOE	4	16-01707	Grubbs-Williams et al v. Janssen Pharmaceuticals, Inc. et al Opposed 12/19/16

MOE	4	16-01766	Seamon v. Janssen Pharmaceuticals, Inc. et al
NEVADA			
NV	2	16-02417	Nockowitz v. Janssen Pharmaceuticals, Inc., et al
OHIO NORTHERN			
OHN	1	16-02476	Carlson et al v. Janssen Pharmaceuticals, Inc.
TENNESSEE EASTERN			
TNE	1	16-00407	Ryan v. Janssen Pharmaceuticals, Inc. et al
TENNESSEE MIDDLE			
TNM	3	16-03052	Adams v. Janssen Pharmaceuticals, Inc.
TNM	3	16-03053	Price v. Janssen Pharmaceuticals, Inc.